OBJECTIVE: To investigate the expression and clinical significance of TRAP1 (tumor necrosis factor receptor-associated protein 1) in kidney cancer. METHODS: TRAP1 expression was detected in kidney cancer and normal kidney tissues by qRT-PCR and immunohistochemistry (IHC), respectively. Then, the correlation of TRAP1 expression with clinicopathological characters and patients' prognosis was evaluated in kidney cancer. RESULTS: IHC results revealed that the high-expression rates of TRAP1 in kidney cancer tissues and normal kidney tissues were 51.3% (41/80), 23.3% (7/30), and the difference was statistically significant (P=0.01). Also, TRAP1 mRNA level in kidney cancer was found to be significantly greater compared with those in normal kidney by qRT-PCR. In addition, TRAP1 expression in kidney cancer significantly correlated with lymph node metastasis and clinical stage (P<0.05). Kaplan-Meier survival analysis indicated that the mean survival time of patients with TRAP1 low-expression was significantly higher (56 months) than those patients with TRAP1 high-expression (47 months). Meanwhile, Kaplan-Meier and Cox survival analysis indicated that TRAP1, lymph node metastasis and clinical stage were correlated with patients' prognosis. CONCLUSION: TRAP1 is highly expressed in kidney cancer and correlates with patients prognosis, which may be served as a potential marker for the diagnosis and treatment of kidney cancer.
OBJECTIVE: To investigate the expression and clinical significance of TRAP1 (tumor necrosis factor receptor-associated protein 1) in kidney cancer. METHODS:TRAP1 expression was detected in kidney cancer and normal kidney tissues by qRT-PCR and immunohistochemistry (IHC), respectively. Then, the correlation of TRAP1 expression with clinicopathological characters and patients' prognosis was evaluated in kidney cancer. RESULTS: IHC results revealed that the high-expression rates of TRAP1 in kidney cancer tissues and normal kidney tissues were 51.3% (41/80), 23.3% (7/30), and the difference was statistically significant (P=0.01). Also, TRAP1 mRNA level in kidney cancer was found to be significantly greater compared with those in normal kidney by qRT-PCR. In addition, TRAP1 expression in kidney cancer significantly correlated with lymph node metastasis and clinical stage (P<0.05). Kaplan-Meier survival analysis indicated that the mean survival time of patients with TRAP1 low-expression was significantly higher (56 months) than those patients with TRAP1 high-expression (47 months). Meanwhile, Kaplan-Meier and Cox survival analysis indicated that TRAP1, lymph node metastasis and clinical stage were correlated with patients' prognosis. CONCLUSION:TRAP1 is highly expressed in kidney cancer and correlates with patients prognosis, which may be served as a potential marker for the diagnosis and treatment of kidney cancer.
Authors: Dongxia Liu; Jiangting Hu; Jackeline Agorreta; Alfredo Cesario; Yuanchao Zhang; Adrian L Harris; Kevin Gatter; Francesco Pezzella Journal: Cancer Lett Date: 2010-05-14 Impact factor: 8.679
Authors: Silje Fismen; Dhivya Thiyagarajan; Natalya Seredkina; Henrik Nielsen; Søren Jacobsen; Thomas Elung-Jensen; Anne-Lise Kamper; Steinar D Johansen; Elin S Mortensen; Ole P Rekvig Journal: Am J Pathol Date: 2012-12-27 Impact factor: 4.307
Authors: Ru Chen; Sheng Pan; Keith Lai; Lisa A Lai; David A Crispin; Mary P Bronner; Teresa A Brentnall Journal: World J Gastroenterol Date: 2014-12-07 Impact factor: 5.742
Authors: Jae Joon Han; Sun Kyung Baek; Jae Jin Lee; Gou Young Kim; Si-Young Kim; Suk-Hwan Lee Journal: Cancer Res Treat Date: 2014-01-15 Impact factor: 4.679